<DOC>
	<DOCNO>NCT02440425</DOCNO>
	<brief_summary>The purpose study find combination Paclitaxel per week Pembrolizumab every 3 week help participant disease . Researchers want find effectiveness drug combination improve delay cancer progression death compare historical data weekly paclitaxel alone , assess safety .</brief_summary>
	<brief_title>Dose Dense Paclitaxel With Pembrolizumab ( MK-3475 ) Platinum Resistant Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Must confirmation histologic diagnosis highgrade ( grade 23 ) epithelial , nonmucinous , nonborderline , ovarian , fallopian tube , primary peritoneal carcinoma . May base original pathology report review original slide . Willing able provide write informed consent/assent authorization ≥ 18 year age day sign informed consent Disease must persistent recur within 6 month prior platinum therapy . Disease may progress prior platinum therapy ( i.e. , refractory ) . Have measurable disease detectable ( nonmeasureable ) disease Measurable disease : must least one `` target lesion '' use assess response protocol . Prior Therapy : Have one prior platinumbased chemotherapeutic regimen management primary disease contain carboplatin , cisplatin , another organoplatinum compound . This initial treatment may include intraperitoneal therapy , consolidation , noncytotoxic agent ( biologic/ target ) extend therapy administer surgical nonsurgical assessment . If patient treat initially paclitaxel primary disease , give weekly every 3 week . The recent therapy therapy subsequent initial therapy , however , contain weekly paclitaxel . If immediate prior ( recent therapy ) initial therapy , may weekly paclitaxel . Allowed receive ( required receive ) , 2 additional cytotoxic regimens management recurrent persistent disease , 1 nonplatinum regimen . Treatment weekly paclitaxel recurrent persistent disease NOT allow . Allowed receive ( required receive ) , noncytotoxic ( biologic/targeted ) therapy part primary treatment regimen . Allowed receive ( required receive ) , noncytotoxic ( biologic/targeted ) therapy part treatment recurrent persistent disease and/or treatment recurrent persistent disease . If noncytotoxic ( biologic/targeted ) therapy give alone ( i.e. , combination cytotoxic chemotherapy ) NOT count prior regimen . Have tissue archival tissue sample identify confirm available study , newly obtain core excisional biopsy tumor lesion Have receive 1 prior regimen must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 . If receive 2 3 prior regimen , must ECOG Performance Status 0 1 . Adequate organ function define protocol Recovery effect recent surgery , radiotherapy , chemotherapy : Should free active infection require antibiotic ( exception uncomplicated UTI ) ; Any hormonal therapy direct malignant tumor must discontinue least 2 week prior registration ( continuation hormone replacement therapy permit ) ; Any prior therapy direct malignant tumor , include chemotherapy , biologic/targeted immunologic agent , must discontinue least 2 week prior registration least 3 week day 1 trial . Women Childbearing Potential ( WOCBP ) : Negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . WOCBP willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Have lowgrade nonepithelial cancer , mucinous cancer , and/or borderline lowmalignant potential cancer Currently participate in/have participate study investigational agent use investigational device within 4 week first dose treatment Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment Had prior monoclonal antibody within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due prior therapy Had prior chemotherapy , target small molecule therapy , radiation therapy within 3 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : If receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . History invasive malignancy ( exception nonmelanoma skin cancer situ cancer undergo potentially curative therapy ) exclude evidence malignancy present within last 3 year . Patients also exclude previous cancer treatment contraindicate protocol therapy . Have receive prior radiotherapy portion abdominal cavity pelvis OTHER THAN treatment ovarian , fallopian tube , primary peritoneal cancer within last 3 year exclude . Prior radiation localize cancer breast , head neck , skin permit , provide complete 3 year prior registration , patient remain free recurrent metastatic disease . Have receive prior chemotherapy abdominal pelvic tumor OTHER THAN treatment ovarian , fallopian tube , primary peritoneal cancer within last 3 year . May receive prior adjuvant chemotherapy localize breast cancer , provide complete 3 year prior registration , patient remain free recurrent metastatic disease . History synchronous endometrial cancer unless follow condition meet : Stage great IA ( FIGO 2010 stag criterion ) ; superficial myometrial invasion ( &lt; 50 % ) , without vascular lymphatic invasion ; poorly differentiate subtypes , include papillary serous , clear cell FIGO Grade 3 lesion great 3 year since diagnosis recurrence . Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Patients previously treat brain metastasis may participate provide stable ( without evidence progression image least 4 week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . Active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( e.g. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment.. Evidence interstitial lung disease , active , noninfectious pneumonitis , know active tuberculosis An active infection require systemic therapy History current evidence condition , therapy , laboratory abnormality might confound result trial , interfere participation full duration trial , best interest participant , opinion treat physician principal study investigator . Known psychiatric substance abuse disorder would interfere cooperation requirement trial Pregnant breastfeeding , expect conceive child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . Received prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody Known history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) Known active Hepatitis B Hepatitis C Received live vaccine within 30 day prior first dose trial treatment Peripheral neuropathy Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 high Known hypersensitivity pembrolizumab excipients Known hypersensitivity paclitaxel Has history ( noninfectious ) pneumonitis require steroid current pneumonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>platinum resistant</keyword>
	<keyword>recurrent</keyword>
	<keyword>persistent</keyword>
	<keyword>epithelial</keyword>
	<keyword>ovarian</keyword>
	<keyword>fallopian tube</keyword>
	<keyword>primary peritoneal</keyword>
	<keyword>carcinoma</keyword>
</DOC>